Spectral Medical (TSE:EDT) has released an update.
Spectral Medical has successfully enrolled 135 patients in its Phase 3 Tigris trial, which aims to evaluate the use of Polymyxin B Hemoperfusion for treating septic shock. With only 15 more participants needed, the company anticipates completing the trial by the end of 2024. This significant progress in patient enrollment highlights Spectral’s commitment to advancing its innovative treatment for septic shock.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
